4D Molecular Therapeutics (FDMT) FCF Margin (2020 - 2026)
4D Molecular Therapeutics' (FDMT) quarterly FCF Margin came in at 2235.81% in Q1 2026, up 33989277.0% year-on-year from N/an in Q1 2025, and down 7951.62% on a QoQ basis from 28.48% in Q4 2025.
4D Molecular Therapeutics (FDMT) FCF Margin (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has 7 years of FCF Margin data on file, last reported at 2235.81% in Q1 2026.
- On a quarterly basis, FCF Margin rose 33989277.0% year-over-year to 2235.81% in Q1 2026; TTM through Mar 2026 was 152.12%, a 68015657.0% increase from a year earlier, with the FY2025 full-year figure at 133.8%, up 37384188.0% from the prior year.
- FCF Margin for Q1 2026 stood at 2235.81%, down from 28.48% in the prior quarter.
- Over the last five years, FCF Margin for FDMT reached as high as 119273.68% in Q4 2023 and fell as low as 4681200.0% in Q4 2024.
- Historically, FCF Margin has averaged 414527.6% across 5 years, with a median of 9704.03% in 2023.
- Across the five-year window, FCF Margin tumbled 480047368 bps in 2024 and surged 468122848 bps in 2025, its largest moves.
- Year by year, FCF Margin stood at 1746.11% in 2022, then soared by 6931 bps to 119273.68% in 2023, then tumbled by 4025 bps to 4681200.0% in 2024, then soared by 100 bps to 28.48% in 2025, then slumped by 7952 bps to 2235.81% in 2026.
- Per Business Quant data, the three most recent FCF Margin figures were 2235.81% in Q1 2026, 28.48% in Q4 2025, and 51563.33% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | 4D Molecular Therapeutics | 706.51 Mn | 315.62 Mn | - | -2,235.81% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,235.81% |
| Dec 31, 2025 | 28.48% |
| Sep 30, 2025 | -51,563.33% |
| Jun 30, 2025 | -292,893.33% |
| Mar 31, 2025 | -342,128.57% |
| Dec 31, 2024 | -4,681,200.00% |
| Sep 30, 2024 | -1,038,966.67% |
| Jun 30, 2024 | -611,840.00% |
| Mar 31, 2024 | -106,421.43% |
| Dec 31, 2023 | 119,273.68% |
| Sep 30, 2023 | -15.25% |
| Jun 30, 2023 | -8,939.33% |
| Mar 31, 2023 | -9,704.03% |
| Dec 31, 2022 | -1,746.11% |
| Sep 30, 2022 | -2,597.80% |
| Jun 30, 2022 | -13,561.73% |
| Mar 31, 2022 | -2,458.00% |
| Dec 31, 2021 | -29,273.91% |
| Sep 30, 2021 | -1,419.33% |
| Jun 30, 2021 | -112.53% |